Intraocular matrix metalloproteinase 2 and 9 in patients with diabetes mellitus with and without diabetic retinopathy

Archives of Medical Science

Volumn 6, Issue 3, 2010, Pages 375-381

  Kłysik, Anna B ^a   Naduk Kik, Julia ^a   Hrabec, Zbigniew ^a   Goś, Roman ^a   Hrabec, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aqueous humour; Diabetes mellitus; Diabetic retinopathy; Metalloproteinase 2; Metalloproteinase 9; Zymography

Indexed keywords

GELATINASE A; GELATINASE B;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; DENSITOMETRY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; HUMAN; MALE; PROLIFERATIVE RETINOPATHY; PROTEIN CONTENT; RETINA MACULOPATHY; ZYMOGRAPHY;

EID: 77954276439     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.14258     Document Type: Article

References (29)

1. Hrabec E, Strȩk M. Human matrix metalloproteinase family: domain structure, substrate specificity and their expression pattern in normal and cancer cells. Curr Pneumol 1997; 1: 73-85.
2. Hrabec E, Naduk J, Strȩk M, Hrabec Z. Type IV collagenases (MMP-2 and MMP-9) and their substrates-intracellular proteins, hormones, cytokines, chemokines and their receptors. Postepy Biochem 2007; 53: 37-45.
3. Zhang G, Fahmy RG, diGirolamo N, Khachigian LM. JUN siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation. J Cell Sci 2006; 119: 3219-26.
4. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 2004; 1: 165-76.
5. Ohno-Matsui K, Uetama T, Yoshida T, et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophtalmol Vis Sci 2003; 44: 5370-5.
6. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14: 2123-33.
7. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9: 267-85.
8. Notari L, Miller A, Martinez A, et al. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophtalmol Vis Sci 2005; 46: 2736-47. (Pubitemid 43086693)
9. Zucker S, Mirza H, Conner CE, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998; 75: 780-6. (Pubitemid 28145828)
10. Descamps FJ, Martens E, Kangave D, et al. The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res 2006; 83: 401-7. (Pubitemid 43850955)
11. Jacqueminet S, Ben Abdesselam O, Chapman MJ, et al. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 2006; 367: 103-7.
12. Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005; 85: 597-607. (Pubitemid 40675441)
13. Ohnishi ST, Barr JK. A simplified method of quantitating proteins using the biuret and phenol reagents. Anal Biochem 1978; 86: 193-200.
14. Hrabec E, Strȩk M, Nowak D, Greger J, Suwalski M, Hrabec Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysys. J Cancer Res Clin Oncol 2002; 128: 197-204. (Pubitemid 34280377)
15. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
16. Wray W, Boulikas P, Wray VP, Hancock R. Silver staining of proteins in polyacrylamide gels. Anal Biochem 1981; 118: 197-203.
17. Hrabec E, Strȩk M, Ziȩba M, Kwiatkowska S, Hrabec Z. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuber Lung Dis 2002; 6: 713-9.
18. Leber TM, Balkwill FR. Zymography: a single step staining method for quantification of proteolytic activity on substrate gels. Anal Biochem 1997; 249: 24-8.
19. Hrabec E, Strȩk M, Nowak D, Hrabec Z. Elevated levels of circulating matrix metalloproteinase-9 in patients with lung cancer. Respiratory Medicine 2001; 95: 1-4. (Pubitemid 32621978)
20. Noda K, Ishida S, Inoue M, et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2003; 44: 2163-9. (Pubitemid 36520313)
21. Salzman J, Limb A, Khaw P, et al. Matrix metallo-proteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. J Ophthalmol 2000; 84: 1091-6.
22. De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci 1998; 39: 1256-60. (Pubitemid 28247362)
23. Kosano H, Okano T, Katsura Y, et al. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 1999; 64: 2307-15.
24. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001; 21: 28-33. (Pubitemid 32151759)
25. Sethi CS, Bailey TA, Luthert PJ, Chong NH. Matrix metalloproteinases biology applied to vitreoretinal disorders. J Ophthalmol 2000; 84: 654-66.
26. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999; 40: 809-13.
27. Campochiaro PA. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest Ophthalmol Vis Sci 2006; 47: 462-74.
28. Yamada E, Tobe T, Yamada H, et al. TIMP-1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol 2001; 16: 87-97. (Pubitemid 32094026)
29. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007; 67: 3310-9. (Pubitemid 46724870)